Personalis, Inc.
PSNL · XNASCIK 1527753fmd_1JTJMG2PF82BW4RGSW61MMMAREServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 9 | 38 | 65 | 79 | 85 | 65 | 73 | 85 | 70 |
| Cost of revenue | 12 | 26 | 43 | 59 | 54 | 52 | 55 | 58 | 54 |
| Gross profit | (2) | 12 | 22 | 20 | 32 | 13 | 18 | 27 | 16 |
| Research and development | 10 | 14 | 22 | 29 | 49 | 65 | 65 | 49 | 50 |
| Selling, general and administrative | 10 | 11 | 22 | 34 | 48 | 64 | 50 | 46 | 54 |
| Operating income | (22) | (14) | (22) | (42) | (65) | (116) | (110) | (68) | (88) |
| Interest expense | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 2 | 1 | 0 | 2 | 6 | 6 | 7 |
| Other non-operating income (expense) | (0) | 0 | (1) | (0) | (0) | 0 | (4) | (18) | (0) |
| Income before taxes | (24) | (20) | (25) | (41) | (65) | (113) | (108) | (81) | (81) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (24) | (20) | (25) | (41) | (65) | (113) | (108) | (81) | (81) |
| Net income | (24) | (20) | (25) | (41) | (65) | (113) | (108) | (81) | (81) |
| Net income to common shareholders | (24) | (20) | (25) | (41) | – | – | – | – | – |